Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears Thoratec's Vectra Access Graft:

This article was originally published in Clinica

Executive Summary

Thoratec Laboratories has received 510(k) marketing clearance from the US FDA for its Vectra Vascular Access Graft. The device incorporates the Pleasanton, California-based company's biomaterial, Thoralon, and is designed to provide access to the bloodstream in end-stage renal disease patients undergoing haemodialysis. It has been available in Japan, Australia and Canada for several years, and in Europe since last year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT069497

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel